Targeted Covalent Inhibitors for Drug Design
The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible association is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein. Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicological consequences of protein haptenization have hindered the development of the TCI concept. Recently, approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerged, thus stimulating interest in the field and leading to authorization of the first cadre of TCIs to be marketed. The covalent inhibitor approach is rapidly gaining acceptance as a valuable tool in drug discovery, and is poised to make a major impact on the design of enzyme inhibitors and receptor modulators.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the oxidation of drugs such as furosemide, isoniazid, acetaminophen, halothane, and model hepatotoxins via cytochrome P-450 can lead to hepatotoxic effects in animals and humans [131, 132].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [132]
Citations
Cites
The growing applications of click chemistry
Moses, J. E., & Moorhouse, A. D. (2007) · Chem. Soc. Rev. · doi:10.1039/b613014n · Cited by 2,367
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Self-citationCommon and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Self-citationStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citation
Research works printed but not linked: 7
- Parmar S., 2014, Pharm. Ther., 39, 483
- Johansson M. H., 2012, Mini-Rev. Med. Chem., 12, 1330
- Campuzano I. D. G., 2015, J. Biomol. Screening, 1
- Guerciolini R., 1997, Int. J. Obes., 21, 12
- Kumar S., 2008, Curr. Opin. Drug Discovery Dev., 11, 43
- Strelevitz T. J., 2015, Drug Metab. Rev., 47, 59
- The Wall Street Journal December 2 2015.
Cited by
Items 501–600 of 618
Computational support of structure-based targeted covalent inhibitor design
Abel, R., & Friesner, R. A. (2021) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2021.01.001 · Cited by 2
Prospects of Covalent Approaches in Drug Discovery: An Overview
Ramachandran, B., Saravanan, M., & Jeyakanthan, J. (2021) · Wiley eBooks · doi:10.1002/9781119654803.ch15 · Cited by 1
Affinity‐Driven Covalent Modulator of the Glyceraldehyde‐3‐Phosphate Dehydrogenase (GAPDH) Cascade
Chern, J., Lu, C., Fang, Z., Chang, C., Hua, K., Chen, Y., Ng, C. Y., Chen, Y. S., Lam, Y., & Wu, S. (2018) · Angewandte Chemie · doi:10.1002/ange.201801618 · Cited by 1
Ren, Y., Xin, Y., Zhu, R., Zhang, Y., Han, L., & Zhao, Y. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109017 · Cited by 1
Shaping the future of constrained peptides and compact proteins in drug discovery
Ullrich, S. (2025) · Australian Journal of Chemistry · doi:10.1071/ch25122 · Cited by 1
Shunmugam, L. (2019) · ResearchSpace (University of KwaZulu-Natal) · Cited by 2
DNA-encoded Libraries with Covalent Warheads
Liu, S., Jin, R., Duan, Z., & Lu, X. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016032-00119 · Cited by 1
Highly Efficient Cell‐Penetrating Probes of Protein Arginine Deiminases for Functional Proteomics
Pathak, S. K. (2018) · ChemBioChem · doi:10.1002/cbic.201800257
Discovery Of Piperlongumine Derivatives As Anti-Leukemic And Anti-Prostate Cancer Agents
Liao, Y. (2018) · Human Biology
Junior, J. C. Q. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.75.2019.tde-05062019-154535 · Cited by 2
Baccalaureate and Higher Degree Program's Accreditation Committee reports on evaluation data.
Schultz, C. M., & Niedringhaus, L. (1995) · PubMed
Design, Synthesis and Evaluation of Covalent Inhibitors for Tissue Transglutaminase and Factor XIIIa
Akbar, A. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-23888
Kneller, D. W. (2019) · Digital Archive @ GSU · doi:10.57709/15900518
In Vivo Targeting of Endogenous Proteins with Reactive Small Molecules
Shindo, N., & Ojida, A. (2019) · Wiley eBooks · doi:10.1002/9783527344406.ch10
Aluri, K. C. (2020) · Digital Repository Service (Northeastern University) · doi:10.17760/d20361345
Myrthil, N. (2019) · Digital Repository Service (Northeastern University) · doi:10.17760/d20317957
Modulating the Reactivity of Electrophilic Warheads for Pharmacokinetic Efficacy
Bogatchenko, M. (2018) · TSpace (University of Toronto)
Rowlands, R. A. (2020) · Deep Blue (University of Michigan)
α-Methylene-β-Lactone Probe for Measuring Live-Cell Reactions of Small MoleculesPreprint
Wang, L., Riel, L. P., Bajrami, B., Deng, B., Howell, A. R., & Yao, X. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12078582.v1
Li, A. P. (2021) · Wiley eBooks · doi:10.1002/9781119171003.ch8
Introduction to proteomics for chemical biology
Wang, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821433-6.00005-2 · Cited by 1
Awoonor‐Williams, E. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-zpp2j
Inhibition studies on the human 20S proteasome: molecular insights from a computational approach
Serrano-Aparicio, N. (2022) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14122.2022.684242
Donnelly, D. P. (2019) · Digital Repository Service (Northeastern University) · doi:10.17760/d20316343
Stabilized Peptide Covalent Inhibitors
Li, Z., Zhao, H., & Wan, C. (2021) · Wiley eBooks · doi:10.1002/9783527343430.ch5
α-Methylene-β-Lactone Probe for Measuring Live-Cell Reactions of Small MoleculesPreprint
Wang, L., Riel, L. P., Bajrami, B., Deng, B., Howell, A. R., & Yao, X. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12078582 · Cited by 1
Sarin, R. (2021) · Digital Repository Service (Northeastern University) · doi:10.17760/d20413926
Khojasteh, S. C., Wong, H. H., Zhang, D., & Hop, C. E. C. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-10691-0_2
Rational Design and Synthesis of Covalent Inhibitors for Mycobacterium tuberculosis Isocitrate Lyase
Torres, D. G. (2021) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.22777166
de Souza, S. F. D. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.82.2021.tde-10112022-160330
Approaching novel antibiotic targets using peptidomimetics
Paulussen, F. M. (2023) · doi:10.5463/thesis.473
Erdogan, F., Chowdhury, R., Beldar, S., Chandy, T. B., Allan, R. G., de Araujo, E. D., & Gunning, P. T. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-hfntq
Synthesis of non-natural amino acids as covalent inhibitors for protein-protein interactions.
Dladla, S. A. (2023) · ResearchSpace (University of KwaZulu-Natal) · doi:10.29086/10413/22604
Aljoundi, A. (2021) · ResearchSpace (University of KwaZulu-Natal) · doi:10.29086/10413/22663
Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IXPreprint
Vaškevičius, A., Baronas, D., Leitāns, J., Kvietkauskaitė, A., Rukšėnaitė, A., Manakova, E., Toleikis, Z., Kaupinis, A., Kazāks, A., Gedgaudas, M., et al. (2024) · eLife · doi:10.7554/elife.101401.1
Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IXPreprint
Vaškevičius, A., Baronas, D., Leitāns, J., Kvietkauskaitė, A., Rukšėnaitė, A., Manakova, E., Toleikis, Z., Kaupinis, A., Kazāks, A., Gedgaudas, M., et al. (2024) · eLife · doi:10.7554/elife.101401.2 · Cited by 1
Lin, L., Lin, K. F., Chen, L., Wang, Y., Xu, L., Li, E., Liu, Q., Zou, H., & Dong, G. (2025) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928356643241216132041
Rothstein, A., Chorghade, M. S., Ibrahim, H., Ganesan, A., Erhardt, P., Schnorrenberg, G., & Gruzman, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01466
Mao, B., Zhang, Y., Wang, Y., You, Q., & Guo, X. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0121
CovDocker: Benchmarking Covalent Drug Design with Tasks, Datasets, and Solutions
Peng, Y., Gao, K., He, L., Cong, Y., Liu, H., He, K., & Wu, L. (2025) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/3711896.3736896
Amin, P. H., Vekariya, R. H., Rajani, D. P., & Dhakhda, S. K. (2025) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.70042
Tissue targeting approaches for drug delivery
Zhang, D., Su, D., Alicea-Salas, J. Y., Zang, R., & Wright, M. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00049-2
Drug Receptor Interactions and Physicochemical Forces
Yang, S., & Kar, S. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_2
Ramos‐Guzmán, C. A., & Mulholland, A. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00081-9
Electrophilic Tuning of Novel Pentafluorobenzenesulfonamide Warheads
Tin, G. K. C. (2020) · TSpace (University of Toronto)
Mosoh, D. A. (2025) · Medical Research Archives · doi:10.18103/mra.v14i2.7220
Overview of recent strategic advances in antiviral covalent inhibitors
Wang, B., Wang, S., Zhang, J., Kim, M. S., & Zhan, P. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2642579
Ramos‐Guzmán, C. A., & Mulholland, A. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00076-5
Pharmaceutical development of a medicinal product containing an isocitrate lyase inhibitor
Zhoshybaeva, А., Kozhanova, K., Barakova, A., Beissenbekov, N., Alimova, U., Raheem, S., & Mombekov, S. (2026) · Pharmacia · doi:10.3897/pharmacia.73.e182414
Cauwel, M. (2021) · theses.fr (ABES) · doi:10.70675/e5004e36z3ddfz46c5zafb0z41e7a8835263
Parise, A. (2022) · theses.fr (ABES) · doi:10.70675/9e156438z6819z4345zbfacz177d25ca375f
Development of small molecules modulating the activity of the nucleoside kinase dCK
Yaala, K. B. (2021) · theses.fr (ABES) · doi:10.70675/749d80bcze0abz4780za87czd786c1617d69
Attempts to Achieve Targeted Covalent Inhibition of Hsp90 β
D’Amico, T., Reynolds, T. S., Serwetnyk, M. A., & Blagg, B. S. J. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70290
A Hetero-multivalent Covalent Strategy for Enhanced Pulmonary Fibrosis TherapyPreprint
Ge, G., Zhu, G., Deng, Y., Wu, H., Zhang, H., Zhu, G., Zeng, H., Li, N., Wang, L., Fan, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9244913/v1
Targeting S1P signaling for drug development
Liu, Y., Song, Y., Wang, Y., Wang, J., & Yang, K. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104674
Iuga, E., Gone, N., de Godoy, M. O., Veríssimo, G. C., Agostinetto, G. D. J., Urich, L., Krüger, N., Kronenberger, T., Guido, R. V. C., O’Donoghue, A. J., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.202600007
Niazi, S. K. (2026) · Advanced Physics Research · doi:10.1002/apxr.202600009
Recent advances in the development of small molecule STK33 inhibitors
Upadhyay, D. B., Parmar, M. P., & Patel, H. M. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2688853
Niazi, S. K. (2026) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2026.1799663
Basagni, F., Paolo, M. L. D., Laghezza, A., Cozza, G., Piazzola, F., Facci, L., Marcolin, E., Roggiolani, E., Piemontese, L., Minarini, A., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70405
Hu, X., Hu, T., Loregian, A., Yang, H., Gao, S., & Zhan, P. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00626
Prestreši, L. (2026) · Repository of the University of Ljubljana (University of Ljubljana)
High‐Throughput Technologies for Targeted Covalent Drug Discovery: Recent Advances and Perspectives
Yu, H., Wang, X., Wang, X., & Yin, Y. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71680
Shah, F. (2026) · Lu Zone Ul (Laurentian University)
Luo, M., Ma, L., Luo, G., & Xiang, H. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118506
Ding, W., Brameyer, S., Kirsch, S. H., Sandargo, B., Surup, F., Hacker, S. M., Jung, K., & Sieber, S. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.27.751175
Dahab, M. A., Ashoub, A. F., Ali, R. A., Sallam, A. S., & Mayhoub, A. S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119449
BindingDB (2020) · UC San Diego · doi:10.7270/q27p91z2
BindingDB Entry 50016732: The Ascension of Targeted Covalent Inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q23f4tpf
BindingDB (2025) · UC San Diego · doi:10.7270/q2gx4h91
BindingDB Entry 50020220: Progress on the Pharmacological Targeting of Janus Pseudokinases.
BindingDB (2024) · UC San Diego · doi:10.7270/q2d50sch
BindingDB (2021) · UC San Diego · doi:10.7270/q2c53qdz
BindingDB Entry 50021792: Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1.
BindingDB (2025) · UC San Diego · doi:10.7270/q21v5kn0
BindingDB Entry 50015655: Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein.
BindingDB (2023) · UC San Diego · doi:10.7270/q2988c0r
BindingDB Entry 50009678: Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72.
BindingDB (2021) · UC San Diego · doi:10.7270/q22r3w5z
BindingDB Entry 50020276: Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease.
BindingDB (2024) · UC San Diego · doi:10.7270/q279493g
BindingDB Entry 50023438: Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
BindingDB (2026) · UC San Diego · doi:10.7270/q2h136xb
BindingDB Entry 50015871: Advanced approaches of developing targeted covalent drugs.
BindingDB (2023) · UC San Diego · doi:10.7270/q2df6w53
BindingDB (2024) · UC San Diego · doi:10.7270/q2668jc4
BindingDB (2026) · UC San Diego · doi:10.7270/q2rv0tkm
Metadata
- Authors
- Baillie, T. A.
- Affiliations
- University of Washington (US)
- Corresponding author
- Baillie, Thomas A.
- ORCID
- Baillie, Thomas A.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2016-08-19
- Volume
- 55
- Issue
- 43
- Pages
- 13408-13421
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2517550655
- Cited by
- 578
- References
- 118
- Citations by year
- 2026: 55 · 2025: 77 · 2024: 66 · 2023: 46 · 2022: 49 · 2021: 76 · 2020: 72 · 2019: 52 · 2018: 46 · 2017: 31 · 2016: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- targeted covalent inhibitors, covalent drug design, drug toxicity, enzyme inhibitors, receptor modulators, drug discovery, non-covalent binding
- MeSH terms
- Animals, Enzyme Inhibitors, Humans, Ligands, Protein Kinases, Drug Design, Molecular Structure, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.